Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Division of Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA.
Nutrients. 2022 Jun 21;14(13):2557. doi: 10.3390/nu14132557.
Background: While physiologic estrogen replacement results in increases in areal bone mineral density (aBMD) in hypoestrogenic adolescent girls and young adult women with AN, data are lacking regarding its impact on measures of volumetric BMD (vBMD), bone geometry, and structure. Methods: 23 young women with anorexia nervosa (AN) and 27 normal-weight healthy controls (HC) between 14−25 years old were followed for 12 months. AN participants received transdermal 17β-estradiol (continuously) with 10 days of cyclic oral progesterone (100 mg daily) every month for the study duration (AN-E+). DXA was used to measure aBMD and body composition, high resolution peripheral quantitative CT (HRpQCT) to assess vBMD, bone geometry and structure at the distal radius and tibia, and microfinite element analysis to estimate strength. Results: Groups did not differ for age. Median baseline BMI z-scores were −1.13 (−1.58, −0.38) in AN-E+ vs. 0.08 (−0.40, 0.84) in HC (p < 0.0001). For most HRpQCT parameters and strength estimates, young women with AN receiving physiologic estrogen replacement demonstrated similar changes over 12 months as did normoestrogenic HC. Additionally, radial cortical tissue mineral density, cortical vBMD, and failure load increased (p = 0.01; p = 0.02; p = 0.004 respectively) over 12 months in AN-E+ compared to HC. Conclusions: With physiologic estrogen replacement, bone accrual improved in AN to approximate changes observed in normoestrogenic controls followed without any intervention, with additional benefits observed for cortical tissue mineral density, cortical vBMD, and failure load at the radius in AN vs. controls. Thus, this strategy for estrogen replacement effectively mimics the effects of endogenous estrogen on bone structure and estimated strength.
生理性雌激素替代治疗可使去势的青春期少女和患有 AN 的年轻成年女性的骨矿物质密度(aBMD)增加,但关于其对体积骨密度(vBMD)、骨几何形状和结构的影响的数据尚缺乏。方法:对 23 名患有神经性厌食症(AN)的年轻女性和 27 名健康的体重正常对照者(HC)进行了为期 12 个月的随访。AN 参与者接受了经皮 17β-雌二醇(持续)治疗,并在研究期间每月接受 10 天的周期性口服孕酮(100mg 每日)治疗(AN-E+)。DXA 用于测量 aBMD 和身体成分,高分辨率外周定量 CT(HRpQCT)用于评估桡骨和胫骨远端的 vBMD、骨几何形状和结构,微有限元分析用于估计强度。结果:两组的年龄无差异。AN-E+组的中位数基线 BMI z 评分为-1.13(-1.58,-0.38),而 HC 组为 0.08(-0.40,0.84)(p<0.0001)。对于大多数 HRpQCT 参数和强度估计值,接受生理性雌激素替代治疗的 AN 年轻女性在 12 个月内的变化与未接受任何干预的正常雌激素的 HC 相似。此外,AN-E+组的桡骨皮质组织矿物质密度、皮质 vBMD 和失效负荷在 12 个月内增加(p=0.01;p=0.02;p=0.004),与 HC 相比,AN 中观察到更多的获益。结论:在接受生理性雌激素替代治疗后,AN 患者的骨量增加,接近未接受任何干预的正常雌激素对照者的变化,并且在 AN 中观察到桡骨皮质组织矿物质密度、皮质 vBMD 和失效负荷的额外获益。因此,这种雌激素替代治疗策略有效地模拟了内源性雌激素对骨结构和估计强度的影响。